Berberine Overcomes Gemcitabine-Associated Chemoresistance through Regulation of Rap1/PI3K-Akt Signaling in Pancreatic Ductal Adenocarcinoma

• Principais autores: Keisuke Okuno (Autor), Caiming Xu (Autor), Silvia Pascual-Sabater (Autor), Masanori Tokunaga (Autor), Haiyong Han (Autor), Cristina Fillat (Autor), Yusuke Kinugasa (Autor), Ajay Goel (Autor)
• Formato: Livro
• Publicado em: MDPI AG, 2022-09-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

Gemcitabine (Gem)-based chemotherapy is one of the first-line treatments for pancreatic ductal adenocarcinoma (PDAC). However, its clinical effect is limited due to development of chemoresistance. Various naturally occurring compounds, including Berberine (BBR), provide an anti-cancer efficacy with...